CAR-T Related Cytopenia Profile in Relapsed/Refractory Multiple Myeloma: Results of Patients Treated with ARI0002h, an Academic BCMA-Directed CAR-T Cell

被引：1

作者：

Oliver-Caldes, Aina ^{[1
]}

Gerardo Rodriguez-Lobato, Luis ^{[2
]}

Gonzalez-Calle, Veronica ^{[3
]}

Tovar, Natalia ^{[4
]}

Cabanas, Valentin ^{[5
]}

Rodriguez-Otero, Paula ^{[6
]}

Luis Reguera, Juan ^{[7
]}

Espanol-Rego, Marta ^{[8
]}

Martin-Antonio, Beatriz ^{[9
]}

Zabaleta, Aintzane ^{[10
]}

Lasa, Marta ^{[11
]}

Inoges, Susana ^{[11
]}

Lopez-Diaz de Cerio, Ascension ^{[11
]}

Paiva, Bruno ^{[12
]}

Varea, Sara ^{[13
]}

Saez-Penataro, Joaquin ^{[13
]}

Juan, Manel ^{[8
]}

Rosinol, Laura ^{[14
]}

Prosper, Felipe ^{[15
]}

Moraleda, Jose M. ^{[5
]}

Urbano-Ispizua, Alvaro ^{[16
]}

Pascal, Mariona ^{[8
]}

Mateos, Maria-Victoria ^{[17
]}

Fernandez de Larrea, Carlos ^{[2
]}

机构：

[1] Univ Barcelona, Dept Hematol, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[2] Hosp Clin Barcelona, Dept Hematol, Amyloidosis & Myeloma Unit, Barcelona, Spain

[3] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain

[4] Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Amyloidosis & Myeloma Unit, Barcelona, Spain

[5] Univ Murcia, IMIB Arrixaca, Hosp Clin Univ Virgen Arrixaca, Murcia, Spain

[6] Clin Univ Navarra, CIBER ONC, IDISNA, CCUN,CIMA, Pamplona, Navarra, Spain

[7] Univ Seville, Hosp Univ Virgen Rocio CSIC CIBERONC, UGC Hematol, Inst Biomed Sevilla IBiS, Seville, Spain

[8] Univ Barcelona, Dept Immunol, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[9] Fdn Jimenez Diaz, Inst Invest Sanitaria, Madrid, Spain

[10] Univ Navarra, Clin Univ Navarra, Ctr Invest Med Aplicada, IDISNA,CIBERONC, Pamplona, Spain

[11] Clin Univ Navarra, Ctr Invest Med Aplicada CIMA, CIBERONC Pamplona, IDISNA, Pamplona, Spain

[12] Clin Univ Navarra, Canc Ctr Univ Navarra CCUN, Ctr Invest Med Aplicada CIMA, Inst Invest Sanitaria Navarra IDISNA, Pamplona, Navarra, Spain

[13] Univ Barcelona, IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain

[14] Hosp Clin Barcelona, IDIBAPS, Dept Hematol, Amyloidosis & Myeloma Unit, Barcelona, Spain

[15] Univ Navarra, Clin Univ Navarra, Ctr Invest Med Aplicada, Pamplona, Spain

[16] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

[17] Univ Hosp Salamanca, IBSAL, Canc Res Ctr IBMCC USAL CSIC, Salamanca, Spain

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-166525

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：10347 / 10349

页数：3

共 50 条

[1] Results from a Pilot Study of ARI0002h, an Academic BCMA-Directed CAR-T Cell Therapy with Fractionated Initial Infusion and Booster Dose in Patients with Relapsed and/ or Refractory Multiple Myeloma
Fernandez de Larrea, Carlos
Gonzalez-Calle, Veronica
Cabanas, Valentin
Oliver-Caldes, Aina
Espanol-Rego, Marta
Rodriguez-Otero, Paula
Luis Reguera, Juan
Lopez Corral, Lucia
Inoges, Susana
Martin-Antonio, Beatriz
Paiva, Bruno
Rosinol, Laura
Lopez-Diaz de Cerio, Ascension
Tovar, Natalia
Lopez Parra, Miriam
Gerardo Rodriguez-Lobato, Luis
Varea, Sara
Sanchez Salinas, Andres
Ortiz-Maldonado, Valentin
Perez-Simon, Jose A.
Prosper, Felipe
Juan, Manel
Moraleda, Jose Maria
Mateos, Maria-Victoria
Pascal, Mariona
Urbano-Ispizua, Alvaro
BLOOD, 2021, 138
[2] Correlative Biological Studies Related to the Response, Peak and Persistence of ARI0002h, an Academic BCMA-Directed CAR-T Cell, with Fractionated Initial Infusion and Booster Dose for Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
Oliver-Caldes, Aina
Espanol-Rego, Marta
Zabaleta, Aintzane
Inoges, Susana
Lopez-Diaz de Cerio, Ascension
Gonzalez-Calle, Veronica
Cabanas, Valentin
Martin-Antonio, Beatriz
Perez-Amill, Lorena
Luis Reguera, Juan
Roberto Rodriguez-Madoz, Juan
Rodriguez-Otero, Paula
Benitez-Ribas, Daniel
Mena, Mari-Pau
Lasa, Marta
Gerardo Rodriguez-Lobato, Luis
Gonzalez, Azucena
Rosino, Laura
Moraleda, Jose Maria
Prosper, Felipe
Urbano-Ispizua, Alvaro
Mateos, Maria-Victoria
Juan, Manel
Paiva, Bruno
Pascal, Marional
Fernandez de Larrea, Carlos
BLOOD, 2021, 138
[3] Durable Remission Achieved from Bcma-Directed CAR-T Therapy Against Relapsed or Refractory Multiple Myeloma
Liu, Yarong
Chen, Zhi
Fang, Hongliang
Wei, Runhong
Yu, Kang
Jiang, Songfu
Fu, Weijun
Jiang, Hua
Du, Juan
He, Feng
Xie, Ronglin
Chen, Jing
Wei, Baofeng
Tao, Jin
Wang, Pin
BLOOD, 2018, 132
[4] Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma
Zugas, Ines
Tormo-Ratera, Marta
Oliver-Caldes, Aina
Soler-Perromat, Juan Carlos
Gonzalez-Calle, Veronica
Moreno, David F.
Cabanas, Valentin
Lopez-Munoz, Nieves
Bartolome-Solanas, Alvaro
Espanol-Rego, Marta
Reguera-Ortega, Juan Luis
Rosinol, Laura
Lopez-Corral, Lucia
Tovar, Natalia
Rodriguez-Lobato, Luis Gerardo
Perez, Rosa Maria Alvarez
Varea, Sara
Olesti, Eulalia
Gomez-Grande, Adolfo
Frutos, Laura
Tamayo, Pilar
Juan, Manel
Moraleda, Jose M.
Urbano-Ispizua, Alvaro
Gonzalez-Navarro, E. Azucena
Martinez-Lopez, Joaquin
Mateos, Maria-Victoria
Tomas, Xavier
Setoain, Xavier
de Larrea, Carlos Fernandez
BLOOD ADVANCES, 2025, 9 (03) : 571 - 582
[5] Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe
Munoz, Beatriz Merchan
Martinez-Roca, Alexandra
Ballestar, Nuria
Gallego, Cristina
Martinez-Cibrian, Nuria
Ortiz-Maldonado, Valentin
Rodriguez-Lobato, Luis Gerardo
Albiol, Nil
Ayora, Pilar
Ramos, Carla
Sanchez-Castanon, Maria
Juan, Manel
Delgado, Julio
Reyner, Jordi Esteve
Urbano-Ispizua, Alvaro
Larrea, Carlos Fernandez de
Fernandez-Aviles, Francesc
BLOOD, 2024, 144 : 7619 - 7620
[6] The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Rejeski, Kai
Hansen, Doris K.
Bansal, Radhika
Sesques, Pierre
Ailawadhi, Sikander
Logue, Jennifer M.
Braeunlein, Eva
dos Santos, David M. Cordas M.
Freeman, Ciara L.
Alsina, Melissa
Theurich, Sebastian
Wang, Yucai
Krackhardt, Angela M.
Locke, Frederick L.
Bachy, Emmanuel
Jain, Michael D.
Lin, Yi
Subklewe, Marion
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
[7] Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy
Thibaud, Santiago
Mia, Babu
Van Oekelen, Oliver
Mouhieddine, Tarek H.
Schaniel, Christoph
Ghodke-Puranik, Yogita
Aleman, Adolfo
Upadhyaya, Bhaskar
Lancman, Guido
Lagana, Alessandro
Richard, Shambavi
Rossi, Adriana
Chari, Ajai
Sanchez, Larysa
Rodriguez, Cesar
Cho, Hearn J.
Richter, Joshua
Hoffman, Ronald
Jagannath, Sundar
Parekh, Samir
BLOOD, 2022, 140
[8] The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma
Kai Rejeski
Doris K. Hansen
Radhika Bansal
Pierre Sesques
Sikander Ailawadhi
Jennifer M. Logue
Eva Bräunlein
David M. Cordas dos Santos
Ciara L. Freeman
Melissa Alsina
Sebastian Theurich
Yucai Wang
Angela M. Krackhardt
Frederick L. Locke
Emmanuel Bachy
Michael D. Jain
Yi Lin
Marion Subklewe
Journal of Hematology & Oncology, 16
[9] The CAR-Hematotox Score As a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma
Rejeski, Kai
Hansen, Doris K.
Bansal, Radhika
Sesques, Pierre
Ailawadhi, Sikander
Logue, Jennifer M.
Freeman, Ciara L.
Alsina, Melissa
Theurich, Sebastian
Locke, Frederick L.
Bachy, Emmanuel
Jain, Michael D.
Lin, Yi
Subklewe, Marion
BLOOD, 2022, 140 : 7506 - 7508
[10] Anti-BCMA CAR-T cell immunotherapy for relapsed or refractory multiple myeloma
Zhang, Xiaohui
Ouyang, Chenxi
Sun, Guofeng
Liu, Hongfeng
Qi, Junyuan
Suo, Xiaohui
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (04)

← 1 2 3 4 5 →